Overview

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of treatment in the dose-response study, M10-309 (NCT00667576).
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Collaborator:
Abbott Japan Co.,Ltd
Treatments:
Ergocalciferols